289 related articles for article (PubMed ID: 27168204)
1. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
Burger JA
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
[No Abstract] [Full Text] [Related]
2. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
3. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Wendtner CM
Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
[No Abstract] [Full Text] [Related]
4. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
5. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
6. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
8. Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.
Coutre SE
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):5-6. PubMed ID: 27168203
[No Abstract] [Full Text] [Related]
9. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
11. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
[TBL] [Abstract][Full Text] [Related]
12. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
Nabhan C; Dyer MJ; Rosen ST
Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
[TBL] [Abstract][Full Text] [Related]
13. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
14. Novel agents versus chemotherapy as frontline treatment of CLL.
Piggin A; Bayly E; Tam CS
Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
16. Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?
Ujjani C; Cheson BD
Cancer J; 2019; 25(6):449-454. PubMed ID: 31764127
[TBL] [Abstract][Full Text] [Related]
17. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
18. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A; Faderl S; Keating MJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
[TBL] [Abstract][Full Text] [Related]
20. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Mahon FX
Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
